4,6-Dichloro-5-(4-methoxyphenoxy)pyrimidine | 150727-32-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4,6-Dichloro-5-(4-methoxyphenoxy)pyrimidine
• CAS: 150727-32-5
• 化学式: C₁₁H₈Cl₂N₂O₂
• 分子量: 271.103
• InChiKey: CJBNYGUTYRETPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,6-Dichloro-5-(4-methoxyphenoxy)pyrimidine 在 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 7.0h， 生成
  参考文献：
  名称：

  Synthesis and structure–activity relationships of potent and orally active sulfonamide ETB selective antagonists

  摘要：

  The synthesis and structure-activity relationships of a series of N-pyrimidinyl benzenesulfonamides as ETB selective antagonists are described. N-Isoxazolyl benzenesulfonamide 1a. previously reported,(1) was selected as a lead compound, and isosteric replacement of the isoxazole ring of la with a pyrimidine ring led to the discovery of the highly potent ETB selective antagonist 6e with oral bioavailability. Modification of the terminal aldehyde group at the 6-position of the pyrimidine ring was investigated, and malonate 15b and acylhydrazone 16f were found to be equipotent to aldehyde 6e. Compound 6e showed ETB antagonistic activity on in vivo evaluation. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00305-9
• 作为产物：
  描述：

  5-(4-methoxyphenoxy)-1H-pyrimidine-4,6-dione 在 2,3,5-三甲基吡啶 、 三氯氧磷 作用下， 反应 4.0h， 生成 4,6-Dichloro-5-(4-methoxyphenoxy)pyrimidine
  参考文献：
  名称：

  Synthesis and structure–activity relationships of potent and orally active sulfonamide ETB selective antagonists

  摘要：

  The synthesis and structure-activity relationships of a series of N-pyrimidinyl benzenesulfonamides as ETB selective antagonists are described. N-Isoxazolyl benzenesulfonamide 1a. previously reported,(1) was selected as a lead compound, and isosteric replacement of the isoxazole ring of la with a pyrimidine ring led to the discovery of the highly potent ETB selective antagonist 6e with oral bioavailability. Modification of the terminal aldehyde group at the 6-position of the pyrimidine ring was investigated, and malonate 15b and acylhydrazone 16f were found to be equipotent to aldehyde 6e. Compound 6e showed ETB antagonistic activity on in vivo evaluation. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00305-9

文献信息

• Pyrimidine and quinazoline derivatives
  申请人：Christ Andreas D.

  公开号：US20080045550A1

  公开（公告）日：2008-02-21

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及以下式子的化合物，其中A，R1到R5和G的定义如描述和权利要求中所述，并且其药学上可接受的盐。本发明还涉及含有这些化合物的制药组合物，以及其制备过程和用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• Pyrimidine and Quinazoline Derivatives
  申请人：Christ Andreas D.

  公开号：US20100069413A1

  公开（公告）日：2010-03-18

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及公式中的化合物，其中A、R1至R5和G如描述和权利要求中所定义，并且其药学上可接受的盐。本发明还涉及含有这些化合物的药物组合物，以及制备它们的过程和它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2044054A2

  公开（公告）日：2009-04-08
• US5292740A
  申请人：——

  公开号：US5292740A

  公开（公告）日：1994-03-08
• US7674804B2
  申请人：——

  公开号：US7674804B2

  公开（公告）日：2010-03-09